{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T12:14:21Z","timestamp":1742386461419},"reference-count":44,"publisher":"Impact Journals, LLC","issue":"47","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,10,10]]},"DOI":"10.18632\/oncotarget.20889","type":"journal-article","created":{"date-parts":[[2017,9,15]],"date-time":"2017-09-15T14:31:56Z","timestamp":1505485916000},"page":"82885-82896","source":"Crossref","is-referenced-by-count":6,"title":["<i>Ex vivo<\/i> evaluation of tumor cell specific drug responses in malignant pleural effusions"],"prefix":"10.18632","volume":"8","author":[{"given":"Carl-Olof","family":"Hillerdal","sequence":"first","affiliation":[{"name":"Karolinska Institutet, Department of Laboratory Medicine, Division of Pathology, Karolinska University Hospital, SE-141 86 Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"\u00d6tv\u00f6s","sequence":"additional","affiliation":[{"name":"Karolinska Institutet, Department of Laboratory Medicine, Division of Pathology, Karolinska University Hospital, SE-141 86 Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T\u00fcnde","family":"Szatm\u00e1ri","sequence":"additional","affiliation":[{"name":"Karolinska Institutet, Department of Laboratory Medicine, Division of Pathology, Karolinska University Hospital, SE-141 86 Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sulaf Abd","family":"Own","sequence":"additional","affiliation":[{"name":"Karolinska Institutet, Department of Laboratory Medicine, Division of Pathology, Karolinska University Hospital, SE-141 86 Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunnar","family":"Hillerdal","sequence":"additional","affiliation":[{"name":"G\u00e4vle Hospital, Department of Lung Medicine, 803 24 G\u00e4vle, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c5sa-Lena","family":"Dackland","sequence":"additional","affiliation":[{"name":"Karolinska Institutet, Department of Laboratory Medicine, Division of Pathology, Karolinska University Hospital, SE-141 86 Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katalin","family":"Dobra","sequence":"additional","affiliation":[{"name":"Karolinska Institutet, Department of Laboratory Medicine, Division of Pathology, Karolinska University Hospital, SE-141 86 Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"Hjerpe","sequence":"additional","affiliation":[{"name":"Karolinska Institutet, Department of Laboratory Medicine, Division of Pathology, Karolinska University Hospital, SE-141 86 Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2017,9,15]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/107327480601300402","article-title":"Malignant pleural mesothelioma: a comprehensive review","volume":"13","author":"Simon","year":"2006","journal-title":"Cancer Control"},{"key":"2","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1097\/JTO.0b013e318267223a","article-title":"Prognostic impact of malignant pleural effusion at presentation in patients with metastatic non-small-cell lung cancer","volume":"7","author":"Govindan","year":"2012","journal-title":"J Thorac Oncol"},{"key":"3","doi-asserted-by":"publisher","first-page":"98","DOI":"10.4103\/0973-1075.84529","article-title":"An update in the management of malignant pleural effusion","volume":"17","author":"Shukla","year":"2011","journal-title":"Indian J Palliat Care"},{"key":"4","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1378\/chest.125.3.1103","article-title":"Asbestos and the pleura: a review","volume":"125","author":"Kamp","year":"2004","journal-title":"Chest"},{"key":"5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2006.04.016","article-title":"Malignant pleural effusion, current and evolving approaches for its diagnosis and management","volume":"54","author":"Neragi-Miandoab","year":"2006","journal-title":"Lung Cancer"},{"key":"6","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.lungcan.2015.03.005","article-title":"Demographics, management and survival of patients with malignant pleural mesothelioma in the National Lung Cancer Audit in England and Wales","volume":"88","author":"Peake","year":"2015","journal-title":"Lung Cancer"},{"key":"7","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1111\/crj.12292","article-title":"Prognostic factors affecting survival in non-small cell lung carcinoma patients with malignant pleural effusions","volume":"10","author":"Hazar","year":"2016","journal-title":"Clin Respir J"},{"key":"8","first-page":"36","article-title":"Soluble CD40 in plasma and malignant pleural effusion with non-small cell lung cancer: A potential marker of prognosis","volume":"1","author":"Huang","year":"2005","journal-title":"Chronic Diseases and Translational Medicine"},{"key":"9","first-page":"559","article-title":"Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs (review)","volume":"11","author":"Vougiouka","year":"2004","journal-title":"Oncol Rep"},{"key":"10","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.clon.2013.08.009","article-title":"Malignant mesothelioma, hypoalbuminaemia and the effect of carboplatin\/pemetrexed on survival","volume":"25","author":"Sridharan","year":"2013","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"11","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.rmed.2009.07.019","article-title":"Pemetrexed in the treatment of malignant mesothelioma: results from an expanded access program in Germany","volume":"104","author":"Manegold","year":"2010","journal-title":"Respir Med"},{"key":"12","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1159\/000362222","article-title":"A randomized phase II trial of gemcitabine plus carboplatin: biweekly versus standard schedules in patients with advanced non-small cell lung cancer","volume":"59","author":"Sato","year":"2013","journal-title":"Chemotherapy"},{"key":"13","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.1200\/jco.2008.20.9114","article-title":"Phase III study by the Norwegian Lung Cancer Study Group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer","volume":"27","author":"Sundstr\u00f8m","year":"2009","journal-title":"J Clin Oncol"},{"key":"14","doi-asserted-by":"publisher","first-page":"3543","DOI":"10.1200\/jco.2007.15.0375","article-title":"Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer","volume":"26","author":"Park","year":"2008","journal-title":"J Clin Oncol"},{"key":"15","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.lungcan.2013.11.011","article-title":"Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma","volume":"84","author":"Santoro","year":"2014","journal-title":"Lung Cancer"},{"key":"16","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s10147-013-0619-5","article-title":"Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy","volume":"19","author":"Ichinose","year":"2014","journal-title":"Int J Clin Oncol"},{"key":"17","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/sj.bjc.6604421","article-title":"Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma","volume":"99","author":"Palshof","year":"2008","journal-title":"Br J Cancer"},{"key":"18","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1007\/s12032-014-0458-x","article-title":"Third-line chemotherapy with carboplatin, gemcitabine and liposomised doxorubicin for malignant pleural mesothelioma","volume":"32","author":"Sorensen","year":"2015","journal-title":"Med Oncol"},{"key":"19","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1097\/JTO.0b013e31818b174d","article-title":"Treatment of malignant pleural mesothelioma with carboplatin, liposomized doxorubicin, and gemcitabine: a phase II study","volume":"3","author":"Hjerpe","year":"2008","journal-title":"J Thorac Oncol"},{"key":"20","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/jco.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Paoletti","year":"2003","journal-title":"J Clin Oncol"},{"key":"21","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1186\/1471-2407-14-709","article-title":"Characterization and drug sensitivity profiling of primary malignant mesothelioma cells from pleural effusions","volume":"14","author":"Dobra","year":"2014","journal-title":"BMC Cancer"},{"key":"22","doi-asserted-by":"publisher","first-page":"119","DOI":"10.18632\/genesandcancer.56","article-title":"Drug sensitivity profiling and molecular characteristics of cells from pleural effusions of patients with lung adenocarcinoma","volume":"6","author":"Dobra","year":"2015","journal-title":"Genes Cancer"},{"key":"23","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12967-016-0816-x","article-title":"Human lung adenocarcinoma cell cultures derived from malignant pleural effusions as model system to predict patients chemosensitivity","volume":"14","author":"Fenizia","year":"2016","journal-title":"J Transl Med"},{"key":"24","doi-asserted-by":"publisher","first-page":"25619","DOI":"10.18632\/oncotarget.4627","article-title":"Patient-derived cell models as preclinical tools for genome-directed targeted therapy","volume":"6","author":"Do","year":"2015","journal-title":"Oncotarget"},{"key":"25","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1159\/000226861","article-title":"Clinical correlations with chemosensitivities measured in a simplified tritiated thymidine incorporation assay in patients with malignant effusion","volume":"47","author":"Nakamura","year":"1990","journal-title":"Oncology"},{"key":"26","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.pharmthera.2016.05.007","article-title":"Personalizedcancer models to predict therapeutic response: challenges and a framework for improvement","volume":"165","author":"Beebe","year":"2016","journal-title":"Pharmacol Ther"},{"key":"27","first-page":"125","article-title":"Predictive testing in cancer chemotherapy. II.","volume":"7","author":"De Bruijn","year":"1985","journal-title":"Pharm Weekbl Sci"},{"key":"28","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1080\/1042819031000116607","article-title":"Appraisal of the MTT-based assay as a useful tool for predicting drug chemosensitivity in leukemia","volume":"44","author":"Nathan","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"29","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0022-1759(95)00072-I","article-title":"A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V","volume":"184","author":"Reutelingsperger","year":"1995","journal-title":"J Immunol Methods"},{"key":"30","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/sj.leu.2401061","article-title":"The study of apoptotic cells by flow cytometry","volume":"12","author":"Ormerod","year":"1998","journal-title":"Leukemia"},{"key":"31","doi-asserted-by":"publisher","first-page":"e65903","DOI":"10.1371\/journal.pone.0065903","article-title":"Variation in drug sensitivity of malignant mesothelioma cell lines with substantial effects of selenite and bortezomib, highlights need for individualized therapy","volume":"8","author":"Dobra","year":"2013","journal-title":"PLoS One"},{"key":"32","first-page":"57","article-title":"Chronology of cellular alterations during 7-ketocholesterol-induced cell death on A7R5 rat smooth muscle cells: Analysis by time lapse-video microscopy and conventional fluorescence microscopy","volume":"52","author":"Lizard","year":"2003","journal-title":"Cytometry Part A"},{"key":"33","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/nprot.2008.226","article-title":"Spheroid-based drug screen: considerations and practical approach","volume":"4","author":"Kunz-Schughart","year":"2009","journal-title":"Nat Protoc"},{"key":"34","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1200\/jco.2004.04.077","article-title":"Chemotherapy sensitivity and resistance assays: a systematic review","volume":"22","author":"Aronson","year":"2004","journal-title":"J Clin Oncol"},{"key":"35","doi-asserted-by":"publisher","first-page":"282","DOI":"10.3389\/fonc.2015.00282","article-title":"Prediction of cancer drug resistance and implications for personalized medicine","volume":"5","author":"Efferth","year":"2015","journal-title":"Front Oncol"},{"key":"36","first-page":"615","article-title":"Clonogenic and nonclonogenicchemosensitivity assays","volume":"69","author":"Lippman","year":"1985","journal-title":"Cancer Treat Rep"},{"key":"37","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1126\/science.1252510","article-title":"The cellular and molecular origin of tumor-associated macrophages","volume":"344","author":"Li","year":"2014","journal-title":"Science"},{"key":"38","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12967-016-0816-x","article-title":"Human lung adenocarcinoma cell cultures derived from malignant pleural effusions as model system to predict patients chemosensitivity","volume":"14","author":"Torrisi","year":"2016","journal-title":"J Transl Med"},{"key":"39","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/nrm2236","article-title":"The third dimension bridges the gap between cell culture and live tissue","volume":"8","author":"Stelzer","year":"2007","journal-title":"Nat Rev Mol Cell Biol"},{"key":"40","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.semcancer.2005.05.002","article-title":"Three-dimensional tissue culture models in cancer biology","volume":"15","author":"Kim","year":"2005","journal-title":"Semin Cancer Biol"},{"key":"41","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1040-8428(00)00078-0","article-title":"Apoptosis, cell adhesion and the extracellular matrix in the three-dimensional growth of multicellular tumor spheroids","volume":"36","author":"Indovina","year":"2000","journal-title":"Crit Rev Oncol Hematol"},{"key":"42","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S1040-8428(00)00086-X","article-title":"Multicellular resistance: a paradigm for clinical resistance?","volume":"36","author":"Jardillier","year":"2000","journal-title":"Crit Rev Oncol Hematol"},{"key":"43","doi-asserted-by":"crossref","first-page":"13021","DOI":"10.1074\/jbc.M709698200","article-title":"Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids","volume":"283","author":"Broaddus","year":"2008","journal-title":"J Biol Chem"},{"key":"44","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3341\/kjo.2003.17.1.29","article-title":"A new rapid and non-radioactive assay for monitoring and determining the proliferation of retinal pigment epithelial cells","volume":"17","author":"Heo","year":"2003","journal-title":"Korean J Ophthalmol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.20889","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T13:28:43Z","timestamp":1589203723000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.20889"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,15]]},"references-count":44,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2017,10,10]]}},"alternative-id":["20889","29137310"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.20889","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,15]]}}}